DEA will delay telemedicine restrictions for buprenorphine, Adderall, and other drugs
After receiving 38,000 public comments, the DEA announces a delay in new rules that would have tightened telemedicine access to drugs to treat opioid addiction and ADHD.
The Drug Enforcement Administration is holding off on making sweeping changes to the way certain drugs can be prescribed via telemedicine — for now.
The DEA announced Wednesday that it was temporarily extending its Covid-era emergency telehealth policies, allowing doctors continued leniency in how they prescribe some controlled substances. The affected medications include buprenorphine, the most common medication used to treat opioid addiction, and stimulants like Adderall used to treat ADHD.
What's Your Reaction?
